(4-环丙基哌嗪-1-基)-[4-(吗啉-4-基甲基)苯基]甲酮 | 929622-08-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-环丙基哌嗪-1-基)-[4-(吗啉-4-基甲基)苯基]甲酮
• 中文别名: 巴维桑特
• 英文名称: Bavisant
• 英文别名: (4-cyclopropylpiperazin-1-yl)(4-(morpholinomethyl)phenyl)methanone；(4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone；(4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
• CAS: 929622-08-2
• 化学式: C₁₉H₂₇N₃O₂
• 分子量: 329.442
• InChiKey: BGBVSGSIXIIREO-UHFFFAOYSA-N

物化性质

• 沸点：
  485.2±45.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  36
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8℃

制备方法与用途

Bavisant（JNJ-31001074）是一种口服活性的人H3受体拮抗剂。

反应信息

• 作为反应物：
  描述：

  (4-环丙基哌嗪-1-基)-[4-(吗啉-4-基甲基)苯基]甲酮 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 0.67h， 以68%的产率得到(4-cyclopropylpiperazin-1-yl)(4-(morpholinomethyl)phenyl)methanone dihydrochloride
  参考文献：
  名称：

  CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR

  摘要：

  某些环丙胺是组胺H3调节剂，可用于治疗组胺H3受体介导的疾病。

  公开号：

  US20070066821A1
• 作为产物：
  描述：

  1-环丙基哌嗪盐酸盐 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 21.08h， 生成 (4-环丙基哌嗪-1-基)-[4-(吗啉-4-基甲基)苯基]甲酮
  参考文献：
  名称：

  Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development

  摘要：

  The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H-3 receptor antagonists is described. The compounds described are high affinity histamine H-3 antagonists. Optimization of the physical properties of these histamine H-3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.

  DOI：

  10.1021/ml5005156

文献信息

• NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES
  申请人：Mani S. Neelakandha

  公开号：US20070129351A1

  公开（公告）日：2007-06-07

  The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.

  本发明涉及一种新型的环丙基酰胺衍生物制备方法，用于治疗由组胺受体介导的疾病和病状。
• NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES
  申请人：Mani S. Neelakandha

  公开号：US20070197508A1

  公开（公告）日：2007-08-23

  The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor.

  本发明涉及一种新型制备取代哌嗪基和二氮杂环巴豆酰胺的方法，可用于治疗组织胺受体介导的疾病和病况。
• PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES
  申请人：Choudhury Anusuya

  公开号：US20080171870A1

  公开（公告）日：2008-07-17

  The present invention is directed to a novel process for the preparation of piperazinyl and diazepanyl benzamide derivatives, useful for the treatment of disorders and conditions mediated by a histamine receptor, preferably the H3 receptor.

  本发明涉及一种新颖的制备哌嗪基和二氮平基苯甲酰胺衍生物的方法，用于治疗由组胺受体介导的疾病和病况，优选为H3受体。
• Processes for the preparation of cyclopropyl-amide derivatives
  申请人：Janssen Pharmaceutica NV

  公开号：US08063206B2

  公开（公告）日：2011-11-22

  The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor.

  本发明涉及一种新型的环丙基酰胺衍生物制备方法，用于治疗由组胺受体介导的疾病和病状。
• Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
  申请人：Janssen Pharmaceutica NV

  公开号：US07728129B2

  公开（公告）日：2010-06-01

  The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides of formula (I), as defined in the specification, useful for the treatment of disorders and conditions mediated by the histamine receptor.

  本发明涉及一种用于制备式（I）中所定义的取代哌嗪基和二氮杂环基苯甲酰胺的新型方法，该方法可用于治疗由组胺受体介导的疾病和病症。